Neo-epitopes are important targets for individualized cancer immunotherapy. Recent advancements in next generation sequencing and bioinformatic approaches to predict immunogenicity of neo-epitopes improved target selection for therapy. However, in many cases only a fraction of predicted epitopes generate a specific T-cell response. Therefore, various assay techniques such as ELISpot, MHC-binding, or mass -spectrometry are being applied to confirm and prioritize neo-epitopes for individualized therapies. The ability to create meaningful and truly patient-individualized sets of neo-epitopes ultimately requires high-throughput formats and thus large numbers of small scale, high quality, and low cost peptides, in very short times.
